NO20084081L - Inhibitorer for human immundefekt virus replikasjon - Google Patents

Inhibitorer for human immundefekt virus replikasjon

Info

Publication number
NO20084081L
NO20084081L NO20084081A NO20084081A NO20084081L NO 20084081 L NO20084081 L NO 20084081L NO 20084081 A NO20084081 A NO 20084081A NO 20084081 A NO20084081 A NO 20084081A NO 20084081 L NO20084081 L NO 20084081L
Authority
NO
Norway
Prior art keywords
human immunodeficiency
inhibitors
immunodeficiency virus
virus replication
compounds
Prior art date
Application number
NO20084081A
Other languages
English (en)
Norwegian (no)
Inventor
Youla Stratigoula Tsantrizos
Michael Boes
Christian Brochu
Eric Malenfant
Stephen Mason
Marc Pesant
Craig Fenwick
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38693497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084081(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20084081L publication Critical patent/NO20084081L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20084081A 2006-05-16 2008-09-25 Inhibitorer for human immundefekt virus replikasjon NO20084081L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74731106P 2006-05-16 2006-05-16
PCT/CA2007/000845 WO2007131350A1 (en) 2006-05-16 2007-05-14 Inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
NO20084081L true NO20084081L (no) 2008-12-12

Family

ID=38693497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084081A NO20084081L (no) 2006-05-16 2008-09-25 Inhibitorer for human immundefekt virus replikasjon

Country Status (33)

Country Link
US (1) US7939545B2 (pl)
EP (1) EP2019825B9 (pl)
JP (3) JP5144649B2 (pl)
KR (1) KR20090007755A (pl)
CN (1) CN101448812B (pl)
AR (1) AR060949A1 (pl)
AT (1) ATE479673T1 (pl)
AU (1) AU2007250427B2 (pl)
BR (1) BRPI0711642A2 (pl)
CA (1) CA2650798C (pl)
CL (1) CL2007001392A1 (pl)
DE (1) DE602007008874D1 (pl)
DK (1) DK2019825T3 (pl)
EA (1) EA018655B1 (pl)
EC (1) ECSP088784A (pl)
ES (1) ES2352576T3 (pl)
HR (1) HRP20100553T1 (pl)
IL (1) IL195244A0 (pl)
ME (1) ME01217B (pl)
MX (1) MX2008014459A (pl)
MY (1) MY148534A (pl)
NO (1) NO20084081L (pl)
NZ (1) NZ573526A (pl)
PE (1) PE20080093A1 (pl)
PL (1) PL2019825T3 (pl)
PT (1) PT2019825E (pl)
RS (1) RS51465B (pl)
SI (1) SI2019825T1 (pl)
TW (1) TWI406856B (pl)
UA (1) UA100005C2 (pl)
UY (1) UY30350A1 (pl)
WO (1) WO2007131350A1 (pl)
ZA (1) ZA200808022B (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
BRPI0819328A8 (pt) * 2007-11-15 2016-02-10 Boehringer Ingelheim Int Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
CA2705318C (en) * 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
ES2463720T3 (es) * 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
AU2008323558C1 (en) * 2007-11-16 2014-05-01 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011133707A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
PH12013500015A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
PH12013500011A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2012065963A2 (en) 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
JP2014511859A (ja) * 2011-04-04 2014-05-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス
EP2694160A1 (en) 2011-04-04 2014-02-12 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2742261T3 (es) 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
PH12013502180A1 (en) 2011-04-21 2014-01-06 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013002357A1 (ja) * 2011-06-30 2013-01-03 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6099149B2 (ja) 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
ES2760981T3 (es) 2011-11-15 2020-05-18 St Pharm Co Ltd Antiviral novedoso derivado de pirrolopiridina y un procedimiento de producción para el mismo
WO2013103724A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140094609A1 (en) * 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
JP2016516692A (ja) 2013-03-13 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2014164409A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6268656B2 (ja) 2013-03-14 2018-01-31 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
ES2623904T3 (es) 2013-03-14 2017-07-12 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2654242T3 (es) 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (en) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (en) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
JP2017521455A (ja) * 2014-07-21 2017-08-03 ヴィーブ ヘルスケア ユーケー リミテッド 抗ＨＩＶ作用を有するフェニル及びｔｅｒｔ−ブチル酢酸置換ピリジノン
RU2720145C2 (ru) 2015-05-29 2020-04-24 Сионоги Энд Ко., Лтд. Азотсодержащие трициклические производные, обладающие активностью ингибирования репликации вич
CN107820493A (zh) 2015-07-06 2018-03-20 Viiv保健英国第五有限公司 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
BR112018000179A2 (pt) 2015-07-08 2018-09-04 Viiv Healthcare Uk No 5 Ltd composto, composição, e, método para tratar a infecção pelo hiv.
US20180170904A1 (en) 2015-07-09 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AU2016290205A1 (en) 2015-07-09 2018-01-18 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20190010139A1 (en) 2015-08-07 2019-01-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
KR20180035908A (ko) 2015-08-10 2018-04-06 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서의 이미다조피리딘 매크로사이클
TWI657086B (zh) * 2015-08-11 2019-04-21 英商Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
WO2017025914A1 (en) 2015-08-12 2017-02-16 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA2995042A1 (en) 2015-08-12 2017-02-16 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017029631A1 (en) 2015-08-20 2017-02-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2019515000A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515003A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2019515939A (ja) 2016-05-11 2019-06-13 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2020503348A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2020503352A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2025196739A1 (en) * 2024-03-21 2025-09-25 Varu Hardik L An emtricitabine degradation impurities and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463518A (en) * 1987-09-02 1989-03-09 Otsuka Pharma Co Ltd Antiarrhythmic agent
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
DE69315920T2 (de) * 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
FR2772761B1 (fr) 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
JP2002531549A (ja) * 1998-12-04 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体
AU2001234690A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
CA2547518A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
IL195244A0 (en) 2009-09-22
CN101448812A (zh) 2009-06-03
AR060949A1 (es) 2008-07-23
MY148534A (en) 2013-04-30
CA2650798A1 (en) 2007-11-22
CL2007001392A1 (es) 2008-01-18
ES2352576T8 (es) 2011-11-22
NZ573526A (en) 2012-03-30
JP5144649B2 (ja) 2013-02-13
WO2007131350A1 (en) 2007-11-22
MX2008014459A (es) 2008-11-26
EA200802209A1 (ru) 2009-06-30
PE20080093A1 (es) 2008-03-25
SI2019825T1 (sl) 2011-01-31
JP2014139242A (ja) 2014-07-31
AU2007250427A1 (en) 2007-11-22
EA018655B1 (ru) 2013-09-30
EP2019825B9 (en) 2011-01-26
PL2019825T3 (pl) 2011-02-28
RS51465B (sr) 2011-04-30
JP2009537459A (ja) 2009-10-29
CN101448812B (zh) 2012-07-04
DK2019825T3 (da) 2010-11-22
TW200812997A (en) 2008-03-16
US20080221159A1 (en) 2008-09-11
EP2019825A4 (en) 2009-06-03
BRPI0711642A2 (pt) 2011-11-29
US7939545B2 (en) 2011-05-10
ZA200808022B (en) 2009-09-30
PT2019825E (pt) 2010-11-08
ES2352576T3 (es) 2011-02-21
DE602007008874D1 (de) 2010-10-14
ATE479673T1 (de) 2010-09-15
JP2013060454A (ja) 2013-04-04
TWI406856B (zh) 2013-09-01
JP5530506B2 (ja) 2014-06-25
UY30350A1 (es) 2008-01-02
ECSP088784A (es) 2008-10-31
KR20090007755A (ko) 2009-01-20
EP2019825B1 (en) 2010-09-01
HK1131153A1 (en) 2010-01-15
HRP20100553T1 (hr) 2010-11-30
CA2650798C (en) 2014-01-14
AU2007250427B2 (en) 2012-08-30
EP2019825A1 (en) 2009-02-04
ME01217B (me) 2013-03-20
UA100005C2 (ru) 2012-11-12

Similar Documents

Publication Publication Date Title
NO20084081L (no) Inhibitorer for human immundefekt virus replikasjon
NO20084256L (no) DPP IV inhibitorformuleringer
NO20090438L (no) Hepatit C virus inhibitorer
NO20085218L (no) Nye pyridinanaloger
NO20090447L (no) Hepatittt C virusinhibitorer
NO20090628L (no) Pyridizinon derivativater
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
BR112013020042A2 (pt) inibidores de vírus da hepatite c
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
NO20090453L (no) Hepatitt C Virusinhibitorer
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
NO20090328L (no) Nye forbindelser 385
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20073101L (no) Nye pyridinforbindelser
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
BR112013028679A2 (pt) inibidores do vírus da hepatite c
NO20076682L (no) Nye pyridinanaloger
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GILEAD SECIENCES INC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application